New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: The theory of autoantigen complementarity

Current Opinion in Nephrology and Hypertension

Volumn 14, Issue 3, 2005, Pages 217-222

  Preston, Gloria A ^a   Pendergraft III, William F ^a   Falk, Ronald J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antineutrophil cytoplasmic autoantibody; Autoimmune disease; Complementary protein; Glomerulonephritis; Proteinase 3; Vasculitis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; COMPLEMENTARY RNA; MESSENGER RNA; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

AMINO ACID SEQUENCE; ANCA ASSOCIATED VASCULITIS; ANTIGEN ANTIBODY COMPLEX; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; IMMUNOGENETICS; PATHOPHYSIOLOGY; PR3 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 18844455738     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000165886.93427.b1     Document Type: Review

References (48)

1. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87:4115-4119.
2. Gross WL, Schmitt WH, Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993; 91:1-12.
3. De'Oliviera J, Gaskin G, Dash A, et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25:380-389.
4. Dolman KM, Gans RO, Vervaat TJ, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342:651-652.
5. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989; 135:921-930.
6. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for MPO cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110:955-963.
7. Brouwer E, Huitema MG, Klok PA, et al. AntiMPO-associated proliferative glomerulonephritis: an animal model. J Exp Med 1993; 177:905-914.
8. Heeringa P, Brouwer E, Klok PA, et al. Autoantibodies to MPO aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. Am J Pathol 1996; 149:1695-1706.
9. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? BMJ 1982; 285:606-610.
10. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12-17.
11. Pudifin DJ, Duursma J, Gathiram V, Jackson TF. Invasive amoebiasis is associated with the development of anti-neutrophil cytoplasmic antibody. Clin Exp Immunol 1994; 97:48-51.
12. Falk RJ, Hogan S, Carey TS, Jennette JC. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990; 113:656-663.
13. Benoist C, Mathis D. Autoimmunity: the pathogen connection [news]. Nature 1998; 394:227-228.
14. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9:914-920.
15. Levin MC, Lee SM, Kalume F, et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 2002; 8:509-513.
16. Oldstone MB. Molecular mimicry and autoimmune disease. Cell 1987; 50:819-820.
17. Singh H. Genetic analysis of transcription factors implicated in B lymphocyte development, Immunol Res 1994; 13:280-290.
18. Griffith ME, Coulthart A, Pusey CD. T cell responses to MPO (MPO) and PR3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996; 103:253-258.
19. Pendergraft WF III, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72-79.
20. Mekler LB. [Specific selective interaction between amino acid groups of polypeptide chains]. Biofizika 1969; 14:581-584.
21. Blalock JE. Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA. Trends Biotechnol 1990; 8:140-144.
22. Pendergraft WF III, Pressler BM, Jennette JC, et al. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med 2005; 83:12-25.
23. Ionescu-Drinea M, Serbanescu G, Nicolau C, Voiculescu V. Association of myasthenic and neuritic symptoms following administration of antitetanic serum. Rev Roum Neurol 1973; 10:239-243.
24. Giovanardi Rossi P, Nanni AG, Gambi D, Borromei A. [Juvenile myasthenia gravis of possible post-vaccinal inoculation: study of 2 cases]. Riv Neurol 1976; 46:265-296.
25. Root-Bernstein RS, Dobbelstein C. Insulin binds to glucagon forming a complex that is hyper-antigerac and inducing complementary antibodies having an idiotype-antiidiotype relationship. Autoimmunity 2001; 33:153-169.
26. Lehner B, Williams G, Campbell RD, Sanderson CM. Antisense transcripts in the human genome. Trends Genet 2002; 18:63-65.
27. Van Den Eynde BJ, Gaugler B, Probst-Kepper M, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999; 190:1793-1800.
28. Lavorgna G, Dahary D, Lehner B, et al. In search of antisense. Trends Biochem Sci 2004; 29:88-94. This review on antisense transcripts discusses a report by Shendure et al. and their observation of increased antisense transcripts in cancer tissues (http://arep.med. harvard.edu/twister/ as_htm#hs113916).
29. Mekler LB. On the specific mutual interaction of amino acid residues of polypeptide chains and amino acid residues with codons. Oncology 1973; 27:286-288.
30. Root-Bernstein RS. On the origin of the genetic code. J Theor Biol 1982; 94:895-904.
31. Root-Bernstein RS. Amino acid pairing. J Theor Biol 1982; 94:885-894.
32. Blalock JE, Smith EM. Hydropathic anti-complementarity of amino acids based on the genetic code. Biochem Biophys Res Commun 1984; 121:203-207.
33. Siemion IZ, Stefanowicz P. Periodical changes of amino acid reactivity within the genetic code. Biosystems 1992; 27:77-84.
34. Siemion IZ, Cebrat M, Kluczyk A. The problem of amino acid complementarity and antisense peptides. Curr Protein Pept Sci 2004; 5:507-527.
35. Heal JR, Roberts GW, Raynes JG, et al. Specific interactions between sense and complementary peptides: the basis for the proteomic code. Chembiochem 2002; 3:136-151.
36. Jerne NK. Towards a network theory of the Immune system. Ann Immunol (Paris) 1974; 125C:373-389.
37. Erlanger BF, Cleveland WL, Wassermann NH, et al. Auto-anti-idiotype: a basis for autoimmunity and a strategy for anti-receptor antibodies. Immunol Rev 1986; 94:23-37.
38. Hill BL, Erlanger BF. Monoclonal antibodies to the thyrotropin receptor raised by an autoantiidiotypic protocol and their relationship to monoclonal autoantibodies from Graves' patients. Endocrinology 1988; 122:2840-2850.
39. Erlanger BF. Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images, Int Rev Immunol 1989; 5:131-137.
40. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994; 8:1296-1301.
41. Shoenfeld Y. The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med 2004; 10:17-18. Shoenfeld and coworkers demonstrated in multiple animal models of autoimmunity that antiidiotypes raised against autoantibodies induced the production of anti-antiidiotypes that possessed characteristics of the initial autoantibodies and caused disease after immunization. They hypothesized that antibodies regulate each other by suppressing or augmenting the immune reaction.
42. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14:1303-1311.
43. Westall FC, Root-Bernstein R. Cause and prevention of postinfectious and postvaccinal neuropathies in light of a new theory of autoimmunity. Lancet 1986; 2:251-252.
44. Root-Bernstein RS. Peptide self-aggregation and peptide complementarity as bases for the evolution of peptide receptors: a review. J Mol Recognit 2005; 18:40-49. Root-Bernstein and colleagues widened the definition of complementary peptides to include those whose sequence is determined by reading the nucleoside sequence of complementary mRNA in the alternative 3′-5′. They also formulated the 'duel antigen theory' to delineate how they propose complementary proteins contribute to autoimmune disease.
45. Root-Bernstein R, Rallo A. Antigenic complementarity resulting in idiotype-antiidiotype immune complexes: possible contributor to AIDS pathogenesis and autoimmunity. Autoimmunity 2004; 37:203-210.
46. Blalock JE, Bost KL. Ligand receptor characteristics of peptides encoded by complementary nucleic acids: implications for a molecular recognition code. Recent Prog Horm Res 1988; 44:199-222.
47. Smith LR, Bost KL, Blalock JE. Generation of idiotypic and anti-idiotypic antibodies by immunization with peptides encoded by complementary RNA: a possible molecular basis for the network theory. J Immunol 1987; 138:7-9.
48. Bost KL, Blalock JE. Production of anti-idiotypic antibodies by immunization with a pair of complementary peptides. J Mol Recognit 1989; 1:179-183.